What is Bionter?
Headquartered in Riehen, Switzerland, Bionter operates within the specialized niche of sub-visible particle testing. This area is crucial for quality control and safety across various industries, including pharmaceuticals, biotechnology, and medical devices, where the presence of unintended particles can have significant consequences. Bionter's focus on this precise testing methodology positions it as a key player in ensuring product integrity and regulatory compliance for its clients.
How much funding has Bionter raised?
Bionter has raised a total of $3M across 1 funding round:
Angel/Seed
$3M
Angel/Seed (2022): $3M with participation from Dynamk Capital
Key Investors in Bionter
Dynamk Capital
Dynamk Capital is a New York-based venture capital firm that specializes in investing in life science industrials, focusing on tools, technologies, and services essential for the discovery, development, and production of life-saving therapies. The firm aims to support innovative companies that are advancing the field of life sciences.
What's next for Bionter?
The substantial enterprise-level capital infusion indicates Bionter is poised for a significant scaling phase. This strategic backing will likely fuel advancements in their testing technologies, expansion into new markets, and enhancement of their service offerings. The company's trajectory suggests a move towards solidifying its position as a leader in sub-visible particle detection, potentially through further research and development or strategic partnerships to broaden its impact within the life sciences and related sectors.
See full Bionter company page
